01.08.2023 - Achieved first patient in (FPI) and continuing to enroll CAB-AXL BA3011 in a Phase 2 potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS) Submitted Food & Drug Administration (FDA) meeting request for potentially .
BioAtla (BCAB) to Release Earnings on Tuesday theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
BioAtla, Inc. (NASDAQ:BCAB – Get Free Report) saw a significant growth in short interest during the month of June. As of June 30th, there was short interest totalling 4,620,000 shares, a growth of 25.9% from the June 15th total of 3,670,000 shares. Based on an average daily volume of 531,100 shares, the short-interest ratio is […]
BioAtla Added to Membership of U S Small-Cap Russell 2000® Index itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.